Weil Gotshal wins SINGULAIR patent dispute for Merck

The U.S. District Court for the District of New Jersey has ruled in favor of pharmaceutical company Merck in a patent infringement suit against Teva Pharmaceuticals. Teva was seeking FDA approval to sell a generic version of 4, 5 and 10 mg tablets of SINGULAIR (montelukast sodium), Merck's asthma and allergic rhinitis medicine. In his decision, Judge Garrett E. Brown upheld Merck's patent on SINGULAIR and ruled that Teva committed infringement. Judge Brown also issued an injunction blocking the approval of Teva's generic versions until the August 2012 expiration of the patent. Weil, Gotshal & Manges' partners Matt Powers and Nick Barzoukas represented Merck in the patent infringement lawsuit against Teva filed in February 2007.

Weil Gotshal wins SINGULAIR patent dispute for Merck law.com Fri, Aug 21, 2009